内镜下袖状胃成形术联合生活方式干预治疗代谢功能障碍相关脂肪性肝炎:多中心、假手术对照、随机试验
这项多中心、双盲、假手术对照随机试验将40例经活检证实的代谢功能障碍相关脂肪性肝炎(MASH)患者按1:1随机分组,比较内镜下袖状胃成形术(ESG)联合生活方式干预与假内镜联合生活方式干预的效果。随访72周后,ESG组总体重减轻9.47%±9.38%,假内镜组为3.91%±5.43%(P<.05);ESG组肝硬度下降5.63±7.17 KPa,假内镜组为0.2±5.38 KPa(P<.05)。ESG组脂肪变改善显著优于假内镜组。
要点
- ESG联合生活方式干预较假内镜联合生活方式干预显著降低总体重(9.47%±9.38% vs 3.91%±5.43%,P<.05)。
- ESG组肝硬度下降5.63±7.17 KPa,显著大于假内镜组的0.2±5.38 KPa(P<.05)。
- ESG组脂肪变改善显著优于假内镜组(-0.94±0.87 vs -0.26±0.99,P=.033)。
核心结论
- ESG是促进MASH合并肥胖患者体重减轻的有效且安全的方法,并伴随显著改善。
研究设计与样本
- 多中心、随机、对照、双盲研究,40例经活检证实的MASH患者按1:1随机分为ESG联合生活方式干预组与假内镜联合生活方式干预组。
- 纳入标准包括活检证实的MASH、非酒精性脂肪性肝病活动度评分(NAS)≥3、纤维化分期F0至F3。
- ESG组18例和假内镜组19例完成72周随访。
主要发现
- ESG组总体重减轻9.47%±9.38%,假内镜组为3.91%±5.43%(P<.05)。
- ESG组肝硬度下降5.63±7.17 KPa,假内镜组为0.2±5.38 KPa(P<.05)。
- ESG组脂肪变减少-0.94±0.87,假内镜组为-0.26±0.99(P=.033)。
- NAS评分变化(-1.89±2.11 vs -1.47±2.01)和纤维化分期变化(-0.1±0.91 vs -0.84±1.21)两组间无差异。
- 在体重减轻>10%的患者中,NAS评分显著改善(-4±0.94 vs -0.81±1.62;P<.01),但纤维化分期无显著改善(-0.3±1.06 vs -0.59±1.25)。
关键数值与推荐
- ESG组仅2例患者发生需住院的不良事件,均在72小时内经保守治疗缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is commonly seen in biopsy-proven steatotic liver disease. Lifestyle intervention reaching a weight loss higher than 10% promotes MASH resolution, but this goal is only achieved by a small number of patients. Endoscopic sleeve gastroplasty (ESG) has recently emerged as a safe and effective option to promote weight loss in the obese population. We report the results of a multicenter, randomized, controlled, and double-blind study to evaluate the effectiveness and safety of ESG in patients with MASH. METHODS: Forty patients were randomized 1:1 to ESG plus lifestyle modification vs sham endoscopy (SE) plus lifestyle intervention. Inclusion criteria included biopsy-proven MASH with nonalcoholic fatty liver disease activity score (NAS) ≥3 and fibrosis stage F0 to F3. Eighteen patients from the ESG group and 19 from the endoscopic simulated intervention (ESI) group completed follow-up over 72 weeks. Baseline to end of follow-up changes in body weight, liver tests, liver stiffness (vibration-controlled transient elastography), and liver histology were recorded RESULTS: Total body weight loss (TBWL) was 9.47% (±9.38%) in the ESG group vs 3.91% (±5.43%) in the ESI group (P < .05). Liver stiffness decreased 5.63 (±7.17) KPa in the ESG group vs 0.2 (±5.38) KPa in the ESI group (P < .05). Steatosis was significantly reduced in the ESG group (-0.94 ± 0.87) vs the ESI group (-0.26 ± 0.99) (P = .033). No differences on NAS (-1.89 ± 2.11 vs -1.47 ± 2.01) score or fibrosis (-0.1 ± 0.91 vs -0.84 ± 1.21) was seen. In patients achieving weight loss >10%, we found a significant improvement on NAS score (-4 ± 0.94 vs -0.81 ± 1.62; P < .01), but not in fibrosis stage (-0.3 ± 1.06 vs -0.59 ± 1.25). Only 2 patients from the ESG group had adverse events that required admission; these resolved conservatively in 72 hours. CONCLUSION: ESG is an effective and safe method to promote weight reduction associated with significant improvement in patients with MASH and obesity. CLINICALTRIALS: gov, Number: NCT03426111.
引用
- Abad J, Llop E, Arias-Loste MT, et al. Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With Metabolic Dysfunction-associated Steatohepatitis: A Multicenter, Sham-controlled, Randomized Trial. Clin Gastroenterol Hepatol. 2024. PMID: 39694202. doi:10.1016/j.cgh.2024.10.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。